36results about How to "Good anti-hepatic fibrosis effect" patented technology

The invention relates to the fields of organic synthesis and medicinal chemistry, and in particular to a Cleistanone derivative, a preparation method and its application in the preparation of anti-hepatic fibrosis drugs. The present invention synthesizes a new Cleistanone derivative and discloses its preparation method. Pharmacological experiments show that the Cleistanone derivatives of the present invention have an anti-hepatic fibrosis effect, and have the value of developing anti-hepatic fibrosis drugs.

The invention relates to the technical field of traditional Chinese medicines, and particularly relates to a compound traditional Chinese medicine for intervening hepatic fibrosis and a preparation method thereof. The compound traditional Chinese medicine consists of the following raw materials in parts by weight: 10 to 30 parts of lizard, 10 to 30 parts of radix angelicae sinensis, 10 to 20 parts of vinegar-processed radix bupleuri, 10 to 30 parts of raw radix paeoniae alba, 20 to 50 parts of raw rhizoma atractylodis macrocephalae, 10 to 30 parts of poria cocos, 10 to 30 parts of vinegar-processed turtle shell, 20 to 50 parts of radix salviae miltiorrhizae, 15 to 45 parts of radix paeoniae rubra, 10 to 30 parts of liquorice root, 20 to 50 parts of raw rice sprout, 20 to 40 parts of raw fructus crataegi, 10 to 30 parts of rhizoma corydalis, 10 to 30 parts of deer-horn glue, 20 to 50 parts of spina gleditsiae, 20 to 50 parts of lucid ganoderma, 10 to 30 parts of fructus lycii, 10 to 30 parts of fingered citron, and 10-30 parts of fructus mume. The compound preparation has a remarkable curative effect on hepatic fibrosis caused by deficiency of liver blood and stasis of veins.

The Chinese medicine composition for treating liver fibrillation and liver cirrhosis has active components prepared from red sage, astragalus root, other medicine(s) with function of promoting blood circulation to disperse blood clots, spleen invigorating medicine(s) and vital energy regulating medicine(s). The active comprises are matched with pharmaceutically acceptable carrier or excipient to prepare various preparation forms. The Chinese medicine composition has high practical curative rate in treating liver fibrillation, no recurrence and no toxic side effect.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, and discloses and provides a composition prepared from O-(triazolyl) ethyl derivative (III) and O-(di(2-methylthio-ethyl)amino) ethyl derivative (IV) of Schiglautone A at the weight ratio of 70 to 30, and a method for preparing the composition by mixing the two compounds at the weight ratio of 70 to 30. The pharmacological experiment proves that the composition provided by the invention at 20 [mu] g / ml can obviously inhibit the proliferation of NIH / 3T3 and the proliferation of fibroblasts induced by transforming growth factor-beta 1, and has the effect of resisting hepatic fibrosis, and therefore, the invention further provides the applications of the composition prepared from O-(triazolyl) ethyl derivative (III) and O-(di(2-methylthio-ethyl)amino) ethyl derivative (IV) of Schiglautone A at the weight ratio of 70 to 30 in preparing medicines for resisting hepatic fibrosis.

The invention involves the use of the total flavonoids of the fields to prepare for the treatment of drugs for the treatment of liver fibrosis.Total yellow total flavonoids are an active ingredient extracted from Hypericum Japonicum Thunb.).The present invention further provides a pharmaceutical composition for the treatment of liver fibrosis. The drug composition includes an effective treatment dose as an active ingredients as a field -based yellow flavonoids, and a pharmaceutical acceptable carrier.The present invention shows that through animal experiments, the total flavonoids of the fields have a good anti -liver fibrosis, and have no poisonous side effects. They can be used to prepare drugs for the treatment of liver fibrosis and are used for clinical liver fibrosis.

The invention relates to an anti-hepatic fibrosis drug composite. The anti-hepatic fibrosis drug composite is characterized by comprising the following crude drugs in parts by weight: 5-15 parts of artemisia anomala, 10-20 parts of geranium wilfordii, 1-5 parts of leeches and 1-5 parts of Zhechong. The anti-hepatic fibrosis drug composite disclosed by the invention can be used for preparing the artemisia anomala, the geranium wilfordii, the leeches and the zhechong into a compound according to a traditional Chinese medicine theory, achieves the purpose of anti-hepatic fibrosis through the synergistic action of the drugs on the aspects of anti-inflammation, anti-necrosis, hepatic cells protection, and the like and has the advantages of low price and easiness for popularization.

The invention relates to the field of organic synthesis and medicinal chemistry and discloses a composition consisting of tetrahydropyrrolyl derivatives and morpholinyl derivatives of Virosaine A in a mass ratio of 20:80 and a method for mixing the compounds in a mass ratio of 20:80 to prepare the composition. Pharmacological experiments indicate that the composition provided by the invention in a concentration of 20mu g / ml can remarkably inhibit the NIH / 3T3 proliferation and the fibroblast proliferation induced by transforming growth factor-beta1, and realizes an anti-liver fibrosis effect; and therefore, the invention also provides an application of the composition consisting of tetrahydropyrrolyl derivatives and morpholinyl derivatives of Virosaine A in a mass ratio of 20:80 in preparing anti-liver fibrosis drugs.

The invention discloses a compound traditional Chinese medicine for treating liver fibrosis, and relates to compound traditional Chinese medicines. The compound traditional Chinese medicine comprises,in weight percent, 0.5-2% of spina gleditsiae, 0.5-2% of stir-fried largehead atractylodes rhizomes, 0.5-2% of tangshen roots, 1-3% of membranous milkvetch roots, 0.5-1.5% of common peony roots, 0.5-1.5% of red-rooted salvia roots, 0.3-1% of Chinese angelica roots, 0.3-1% of peach seeds, 0.5-1.5% of turmeric rhizomes and 0.5-1.5% of vinegar turtle. The compound traditional Chinese medicine is prepared from conventional pharmaceutical excipients by a conventional method in the field of pharmacy. The compound traditional Chinese medicine for treating the liver fibrosis can be taken after beingdetected or extracted by water or ethyl alcohol. The medicine can be prepared into medically acceptable oral preparations such as tablets, capsules, granules and the like, and pharmacodynamical research shows that the medicine has the functions of invigorating spleen, supplementing qi, activating blood and dissolving stasis and is an effective and special medicine for treating liver fibrosis.

The invention relates to a method for separating and extracting C15H18O5 from Cichorium glandulosum Boiss.et Hout and use of C15H18O5 the English name of which is 11B, 13-Dihydrolacurin. The method is characterized by comprising the following steps: soaking the root of Cichorium glandulosum Boiss.et Hout by ethanol; collecting the percolate by a percolation method; obtaining a thick extract by a reduced pressure distillation device; passing the extract through a silicagel column, an octadecylsilyl column and a Sephadex LH-20 column; eluting; and drying the eluant by the reduced pressure distillation device to obtain dry powder which is the monomer C15H18O5, the English name of which is 11B, 13-Dihydrolacurin. The compound has the effect of preventing anti-hepatic fibrosis, namely, the compound inhibits activating and proliferating effect of hepatic stellate cells, so that the C15H18O5 with the English name of 11B, 13-Dihydrolacurin can be used as a lead compound for preventing anti-hepatic fibrosis.